Showing promise in the landscape of obesity therapy, retatrutide presents a distinct approach. Unlike many current medications, retatrutide functions as a dual agonist, at once targeting both GLP-like peptide-1 (GLP-1) https://henridrbg510168.iyublog.com/37545080/a-novel-retatrutide-the-glp-gip-binding-site-agonist